Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid β-infused rats relates to the decreases of amyloid β and cholesterol levels in detergent-insoluble membrane fractions

被引:96
作者
Hashimoto, M [1 ]
Hossain, S
Agdul, H
Shido, O
机构
[1] Shimane Univ, Fac Med, Dept Environm Physiol, Izumo, Shimane 6938501, Japan
[2] Jahangirnagar Univ, Dept Biochem & Mol Biol, Dhaka 1342, Bangladesh
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2005年 / 1738卷 / 1-3期
关键词
amyloid beta peptide; detergent-insoluble membrane fraction; docosahexaenoic acid; learning ability; Alzheimer's disease model rats;
D O I
10.1016/j.bbalip.2005.11.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We investigated the effects of dietary administration of docosahexaenoic acid (DHA; C22:6n-3) on the levels of amyloid beta (A beta) peptide (1-40) and cholesterol in the nonionic detergent Triton 100x-insoluble membrane fractions (DIFs) of the cerebral cortex and, also, on learning-related memory in an animal model of Alzheimer's disease (AD) rats infused with A beta peptide (1-40) into the cerebral ventricle. The infusion increased the levels of A beta peptide and cholesterol in the DIFs concurrently with a significant increase in reference memory errors (measured by eight-arm radial-maze tasks) compared with those of vehicle rats. Conversely, the dietary administration of DHA to AD-model rats decreased the levels of A beta peptide and cholesterol in the DlFs, with the decrease being more prominent in the DHA-administered rats. Regression analysis revealed a significant positive correlation between A beta peptide and each of cholesterol, palmitic acid and stearic acid, and between the number of reference memory errors and each of cholesterol, palmitic, stearic and oleic acid; moreover, a significant negative correlation was observed between the number of reference memory errors and the molar ratio of DHA to palmitic plus stearic acid. These results suggest that DHA-induced protection of memory deficits in AD-model rats is related to the interactions of cholesterol, palmitic acid or stearic acid with A beta peptides in DIFs where DHA ameliorates these interactions. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:91 / 98
页数:8
相关论文
共 61 条
[1]   Reduction of cortical amyloid β levels in guinea pig brain after systemic administration of physostigmine [J].
Beach, TG ;
Kuo, YM ;
Schwab, C ;
Walker, DG ;
Roher, AE .
NEUROSCIENCE LETTERS, 2001, 310 (01) :21-24
[2]   Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach [J].
Behl, C ;
Moosmann, B .
FREE RADICAL BIOLOGY AND MEDICINE, 2002, 33 (02) :182-191
[3]   Structure and function of sphingolipid- and cholesterol-rich membrane rafts [J].
Brown, DA ;
London, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (23) :17221-17224
[4]   CHANGES IN ANTIOXIDANT ENZYMES ACTIVITIES, AGGREGABILITY AND MALONYLDIALDEHYDE CONCENTRATION IN BLOOD-PLATELETS FROM PATIENTS WITH CORONARY HEART-DISEASE [J].
BUCZYNSKI, A ;
WACHOWICZ, B ;
KEDZIORAKORNATOWSKA, K ;
TKACZEWSKI, W ;
KEDZIORA, J .
ATHEROSCLEROSIS, 1993, 100 (02) :223-228
[5]  
CADER AA, 1995, INT J BIOCHEM CELL B, V27, P665
[6]   Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model [J].
Calon, F ;
Lim, GP ;
Yang, FS ;
Morihara, T ;
Teter, B ;
Ubeda, O ;
Rostaing, P ;
Triller, A ;
Salem, N ;
Ashe, KH ;
Frautschy, SA ;
Cole, GM .
NEURON, 2004, 43 (05) :633-645
[7]   Plasma membrane ordering agent pluronic F-68 (PF-68) reduces neurotransmitter uptake and release and produces learning and memory deficits in rats [J].
Clarke, MSF ;
Prendergast, MA ;
Terry, AV .
LEARNING & MEMORY, 1999, 6 (06) :634-649
[8]   Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment [J].
Conquer, JA ;
Tierney, MC ;
Zecevic, J ;
Bettger, WJ ;
Fisher, RH .
LIPIDS, 2000, 35 (12) :1305-1312
[9]   Wnt signaling function in Alzheimer's disease [J].
De Ferrari, GV ;
Inestrosa, NC .
BRAIN RESEARCH REVIEWS, 2000, 33 (01) :1-12
[10]  
Eckert GP, 2003, PHARMACOPSYCHIATRY, V36, pS136